Get the Stockscreener App
57.26
1.29%
-0.75
After Hours:
57.26
Ptc Therapeutics Inc stock is traded at $57.26, with a volume of 1.52M.
It is down -1.29% in the last 24 hours and up +12.03% over the past month.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
See More
Previous Close:
$58.01
Open:
$58.61
24h Volume:
1.52M
Relative Volume:
1.28
Market Cap:
$4.55B
Revenue:
$900.66M
Net Income/Loss:
$-453.20M
P/E Ratio:
-9.6397
EPS:
-5.94
Net Cash Flow:
$-274.19M
1W Performance:
+16.08%
1M Performance:
+12.03%
6M Performance:
+10.26%
1Y Performance:
+81.20%
1-Day Range:
$57.08
$58.73
1-Week Range:
$49.38
$58.73
52-Week Range:
$30.59
$58.73
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Name
Ptc Therapeutics Inc
Sector
Industry
Phone
(908) 222-7000
Address
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
57.26 | 4.61B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Truist | Buy |
| May-09-25 | Upgrade | BofA Securities | Neutral → Buy |
| May-07-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-11-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Mar-07-25 | Initiated | Scotiabank | Sector Perform |
| Dec-13-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-03-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Aug-26-24 | Resumed | UBS | Buy |
| May-20-24 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Oct-30-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-27-23 | Downgrade | Citigroup | Neutral → Sell |
| Oct-06-23 | Downgrade | Truist | Buy → Hold |
| Sep-18-23 | Downgrade | Citigroup | Buy → Neutral |
| Sep-15-23 | Downgrade | Raymond James | Outperform → Underperform |
| Mar-17-23 | Initiated | SVB Securities | Market Perform |
| Dec-14-22 | Initiated | Goldman | Sell |
| Sep-12-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-18-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-29-21 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Feb-12-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-05-21 | Upgrade | Citigroup | Neutral → Buy |
| Nov-30-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Oct-30-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Apr-09-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Feb-20-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| May-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Apr-11-19 | Initiated | Bernstein | Outperform |
| Oct-03-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Jun-18-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-04-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-29-18 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-16-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-26-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Oct-09-17 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Ptc Therapeutics Inc Stock (PTCT) Latest News
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Director Sells 1,667 Shares of Stock - MarketBeat
Real time scanner hits for PTC Therapeutics Inc. explained2025 Risk Factors & AI Based Buy and Sell Signals - Newser
Heatmap analysis for PTC Therapeutics Inc. and competitorsJuly 2025 Opening Moves & Reliable Price Action Trade Plans - Newser
What institutional flow reveals about PTC Therapeutics Inc.July 2025 Reactions & Short-Term High Return Strategies - Newser
Is PTC Therapeutics Inc. stock a good pick for beginners2025 Sector Review & Weekly Setup with ROI Potential - خودرو بانک
What to expect from PTC Therapeutics Inc. in the next 30 daysJuly 2025 Setups & Entry Point Confirmation Signals - Newser
Is now a turning point for PTC Therapeutics Inc.Earnings Beat & Safe Entry Zone Identification - Newser
Ieq Capital LLC Buys 38,804 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. $PTCT Position Trimmed by Armistice Capital LLC - MarketBeat
PTC Therapeutics' SWOT analysis: stock poised for growth amid regulatory challenges - MSN
Technical analysis overview for PTC Therapeutics Inc. stockQuarterly Trade Summary & Consistent Profit Trading Strategies - Newser
Applying Wyckoff theory to PTC Therapeutics Inc. stock2025 Winners & Losers & Long-Term Growth Plans - Newser
Real time alert setup for PTC Therapeutics Inc. performanceMarket Trend Summary & Free Weekly Watchlist of Top Performers - Newser
What is PTC Therapeutics Inc.’s valuation compared to sectorJuly 2025 Weekly Recap & Risk Controlled Swing Alerts - خودرو بانک
PTC Therapeutics (NASDAQ:PTCT) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
Institutional scanner results for PTC Therapeutics Inc.Stop Loss & Verified Short-Term Trading Plans - Newser
Ptc Therapeutics stock hits 52-week high at 58.61 USD - Investing.com
Ptc Therapeutics stock hits 52-week high at 58.61 USD By Investing.com - Investing.com Nigeria
Transcript : PTC Therapeutics, Inc. Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-04-2025 11 - MarketScreener
Here's Why Shares in PTC Therapeutics Soared This Week - Mitrade
PTCT Stock Surges After Promising Outlook for Sephience - GuruFocus
Transcript : PTC Therapeutics, Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-03-2025 08 - MarketScreener
Canada Pension Plan Investment Board Increases Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
PDT Partners LLC Has $2.06 Million Stock Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
What momentum shifts mean for PTC Therapeutics Inc.Market Trend Review & Expert-Curated Trade Recommendations - Newser
Using Python tools to backtest PTC Therapeutics Inc. strategiesQuarterly Portfolio Report & Community Supported Trade Ideas - Newser
Can PTC Therapeutics Inc. maintain its current growth rateGold Moves & Consistent Profit Trading Strategies - خودرو بانک
Rafferty Asset Management LLC Sells 20,965 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
Russell Investments Group Ltd. Cuts Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Palo Alto Investors LP Purchases 17,783 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Stock Price Up 6.1%Should You Buy? - MarketBeat
Key metrics from PTC Therapeutics Inc.’s quarterly data2025 Retail Activity & Verified Entry Point Signals - Newser
MPM Bioimpact LLC Grows Stock Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
How to interpret RSI for PTC Therapeutics Inc. stockJuly 2025 Big Picture & Community Consensus Trade Signals - Newser
How to use a screener to detect PTC Therapeutics Inc. breakoutsMarket Movement Recap & Free Weekly Watchlist of Top Performers - Newser
Comparing PTC Therapeutics Inc. in custom built stock radarsInsider Selling & Precise Buy Zone Tips - Newser
Multi asset correlation models including PTC Therapeutics Inc.Trade Analysis Report & Daily Risk Controlled Trade Plans - Newser
Will PTC Therapeutics Inc. price bounce be sustainableOptions Play & Weekly Return Optimization Plans - Newser
Using Bollinger Bands to evaluate PTC Therapeutics Inc.July 2025 Pullbacks & Short-Term Swing Trade Alerts - Newser
What earnings revisions data tells us about PTC Therapeutics Inc.Weekly Stock Analysis & Weekly Setup with High ROI Potential - Newser
PTC Therapeutics, Inc. $PTCT Shares Bought by Driehaus Capital Management LLC - MarketBeat
PTC Therapeutics: A Convergence of Strength in RS Rating, Catalysts, and Institutional Sentiment - AInvest
Combining price and volume data for PTC Therapeutics Inc.Dollar Strength & Community Driven Trade Alerts - Newser
Northern Trust Corp Increases Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
RareMed Expands Partnership with PTC Therapeutics to Enhance Access to Sephience Therapy for PKU Patients - AInvest
Using economic indicators to assess PTC Therapeutics Inc. potentialJuly 2025 Weekly Recap & Weekly Momentum Picks - Newser
Best data tools to analyze PTC Therapeutics Inc. stock2025 Top Decliners & AI Based Buy and Sell Signals - Newser
Ptc Therapeutics Inc Stock (PTCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):